Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 1/2013

01.02.2013 | review

Thymic malignancies focusing on systemic treatment

verfasst von: Gudrun Absenger, MD, Ferdinand Ploner

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Malignancies originating from thymic epithelial tissue are rare and treatment approach depends on the individual situation. There are no randomized trials that provide evidence of therapy for patients with thymoma and thymic carcinoma. Treatment includes surgery, radiation therapy, and systemic therapy. For early stage tumors, surgery is the treatment of choice. Long-term survival depends on histologic type, presence of invasion, and quality of surgical resection. For locally advanced thymomas and thymic carcinomas, multimodal treatment includes neoadjuvant chemotherapy and adjuvant radiation. Patients with metastatic tumors are mainly treated with palliative chemotherapy. The optimal chemotherapy combination has not yet been established, although platinum-based drug regimes show reasonable response rates. For patients with poor performance status, the somatostatin (SST) analog octreotide with high affinity for SST receptors could be a potential treatment alternative. Small trials showed tumor responses, especially in combination with prednisolone. In the last decade, an effort has been made to establish targeted agents in the treatment of thymomas and thymic carcinomas. Nevertheless, up to now these agents have had only limited activity in this rare malignancy.
Literatur
1.
Zurück zum Zitat Engels EA, Pfeiffer RM. Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer. 2003;105(4):546–551.PubMedCrossRef Engels EA, Pfeiffer RM. Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer. 2003;105(4):546–551.PubMedCrossRef
2.
Zurück zum Zitat Schmidt-Wolf IG, Rockstroh JK, Schuller H, Hirner A, Grohe C, Muller-Hermelink HK, et al. Malignant thymoma: current status of classification and multimodality treatment. Ann Hematol. 2003;82(2):69–76.PubMed Schmidt-Wolf IG, Rockstroh JK, Schuller H, Hirner A, Grohe C, Muller-Hermelink HK, et al. Malignant thymoma: current status of classification and multimodality treatment. Ann Hematol. 2003;82(2):69–76.PubMed
3.
Zurück zum Zitat Rosai J. Histological typing of tumours of the thymus. 1999; 2nd ed. Rosai J. Histological typing of tumours of the thymus. 1999; 2nd ed.
4.
Zurück zum Zitat Strobel P, Hohenberger P, Marx A. Thymoma and thymic carcinoma: molecular pathology and targeted therapy. J Thorac Oncol. 2010 Oct;5(10 Suppl 4):S286–90.PubMedCrossRef Strobel P, Hohenberger P, Marx A. Thymoma and thymic carcinoma: molecular pathology and targeted therapy. J Thorac Oncol. 2010 Oct;5(10 Suppl 4):S286–90.PubMedCrossRef
5.
Zurück zum Zitat Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer. 1981 Dec 1;48(11):2485–92.PubMedCrossRef Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer. 1981 Dec 1;48(11):2485–92.PubMedCrossRef
6.
Zurück zum Zitat Gamondes JP, Balawi A, Greenland T, Adleine P, Mornex JF, Zhang J, et al. Seventeen years of surgical treatment of thymoma: factors influencing survival. Eur J Cardiothorac Surg. 1991;5(3):124–31.PubMedCrossRef Gamondes JP, Balawi A, Greenland T, Adleine P, Mornex JF, Zhang J, et al. Seventeen years of surgical treatment of thymoma: factors influencing survival. Eur J Cardiothorac Surg. 1991;5(3):124–31.PubMedCrossRef
7.
Zurück zum Zitat Kim DJ, Yang WI, Choi SS, Kim KD, Chung KY. Prognostic and clinical relevance of the World Health Organization schema for the classification of thymic epithelial tumors: a clinicopathologic study of 108 patients and literature review. Chest. 2005 Mar;127(3):755–61.PubMedCrossRef Kim DJ, Yang WI, Choi SS, Kim KD, Chung KY. Prognostic and clinical relevance of the World Health Organization schema for the classification of thymic epithelial tumors: a clinicopathologic study of 108 patients and literature review. Chest. 2005 Mar;127(3):755–61.PubMedCrossRef
8.
Zurück zum Zitat Souadjian JV, Enriquez P, Silverstein MN, Pepin JM. The spectrum of diseases associated with thymoma. coincidence or syndrome? Arch Intern Med. 1974 Aug;134(2):374–9.PubMedCrossRef Souadjian JV, Enriquez P, Silverstein MN, Pepin JM. The spectrum of diseases associated with thymoma. coincidence or syndrome? Arch Intern Med. 1974 Aug;134(2):374–9.PubMedCrossRef
9.
Zurück zum Zitat Dessypris EN. The biology of pure red cell aplasia. Semin Hematol. 1991 Oct;28(4):275–84.PubMed Dessypris EN. The biology of pure red cell aplasia. Semin Hematol. 1991 Oct;28(4):275–84.PubMed
10.
Zurück zum Zitat Verley JM, Hollmann KH. Thymoma. A comparative study of clinical stages, histologic features, and survival in 200 cases. Cancer. 1985 Mar 1;55(5):1074–86.PubMedCrossRef Verley JM, Hollmann KH. Thymoma. A comparative study of clinical stages, histologic features, and survival in 200 cases. Cancer. 1985 Mar 1;55(5):1074–86.PubMedCrossRef
11.
Zurück zum Zitat Quagliano PV. Thymic carcinoma: case reports and review. J Thorac Imaging. 1996 Winter;11(1):66–74.PubMedCrossRef Quagliano PV. Thymic carcinoma: case reports and review. J Thorac Imaging. 1996 Winter;11(1):66–74.PubMedCrossRef
12.
Zurück zum Zitat Sung YM, Lee KS, Kim BT, Choi JY, Shim YM, Yi CA. 18F-FDG PET/CT of thymic epithelial tumors: usefulness for distinguishing and staging tumor subgroups. J Nucl Med. 2006 Oct;47(10):1628–34.PubMed Sung YM, Lee KS, Kim BT, Choi JY, Shim YM, Yi CA. 18F-FDG PET/CT of thymic epithelial tumors: usefulness for distinguishing and staging tumor subgroups. J Nucl Med. 2006 Oct;47(10):1628–34.PubMed
13.
Zurück zum Zitat Strobel P, Bauer A, Puppe B, Kraushaar T, Krein A, Toyka K, et al. Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. J Clin Oncol. 2004 Apr 15;22(8):1501–9.PubMedCrossRef Strobel P, Bauer A, Puppe B, Kraushaar T, Krein A, Toyka K, et al. Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. J Clin Oncol. 2004 Apr 15;22(8):1501–9.PubMedCrossRef
14.
Zurück zum Zitat Maggi G, Casadio C, Cavallo A, Cianci R, Molinatti M, Ruffini E. Thymoma: results of 241 operated cases. Ann Thorac Surg. 1991 Jan;51(1):152–6.PubMedCrossRef Maggi G, Casadio C, Cavallo A, Cianci R, Molinatti M, Ruffini E. Thymoma: results of 241 operated cases. Ann Thorac Surg. 1991 Jan;51(1):152–6.PubMedCrossRef
15.
Zurück zum Zitat Zhang H, Lu N, Wang M, Gu X, Zhang D. Postoperative radiotherapy for stage I thymoma: a prospective randomized trial in 29 cases. Chin Med J (Engl). 1999 Feb;112(2):136–8. Zhang H, Lu N, Wang M, Gu X, Zhang D. Postoperative radiotherapy for stage I thymoma: a prospective randomized trial in 29 cases. Chin Med J (Engl). 1999 Feb;112(2):136–8.
16.
Zurück zum Zitat Singhal S, Shrager JB, Rosenthal DI, LiVolsi VA, Kaiser LR. Comparison of stages I-II thymoma treated by complete resection with or without adjuvant radiation. Ann Thorac Surg. 2003 Nov;76(5):1635–41; discussion 1641–2.PubMedCrossRef Singhal S, Shrager JB, Rosenthal DI, LiVolsi VA, Kaiser LR. Comparison of stages I-II thymoma treated by complete resection with or without adjuvant radiation. Ann Thorac Surg. 2003 Nov;76(5):1635–41; discussion 1641–2.PubMedCrossRef
17.
Zurück zum Zitat Ogawa K, Uno T, Toita T, Onishi H, Yoshida H, Kakinohana Y, et al. Postoperative radiotherapy for patients with completely resected thymoma: a multi-institutional, retrospective review of 103 patients. Cancer. 2002 Mar 1;94(5):1405–13.PubMedCrossRef Ogawa K, Uno T, Toita T, Onishi H, Yoshida H, Kakinohana Y, et al. Postoperative radiotherapy for patients with completely resected thymoma: a multi-institutional, retrospective review of 103 patients. Cancer. 2002 Mar 1;94(5):1405–13.PubMedCrossRef
18.
Zurück zum Zitat Thomas CR, Wright CD, Loehrer PJ. Thymoma: state of the art. J Clin Oncol. 1999 Jul;17(7):2280–9.PubMed Thomas CR, Wright CD, Loehrer PJ. Thymoma: state of the art. J Clin Oncol. 1999 Jul;17(7):2280–9.PubMed
19.
Zurück zum Zitat Mangi AA, Wright CD, Allan JS, Wain JC, Donahue DM, Grillo HC, et al. Adjuvant radiation therapy for stage II thymoma. Ann Thorac Surg. 2002 Oct;74(4):1033–7.PubMedCrossRef Mangi AA, Wright CD, Allan JS, Wain JC, Donahue DM, Grillo HC, et al. Adjuvant radiation therapy for stage II thymoma. Ann Thorac Surg. 2002 Oct;74(4):1033–7.PubMedCrossRef
20.
Zurück zum Zitat Ariaratnam LS, Kalnicki S, Mincer F, Botstein C. The management of malignant thymona with radiation therapy. Int J Radiat Oncol Biol Phys. 1979 Jan;5(1):77–80.PubMedCrossRef Ariaratnam LS, Kalnicki S, Mincer F, Botstein C. The management of malignant thymona with radiation therapy. Int J Radiat Oncol Biol Phys. 1979 Jan;5(1):77–80.PubMedCrossRef
21.
Zurück zum Zitat Penn CR, Hope-Stone HF. The role of radiotherapy in the management of malignant thymoma. Br J Surg. 1972 Jul;59(7):533–9.PubMedCrossRef Penn CR, Hope-Stone HF. The role of radiotherapy in the management of malignant thymoma. Br J Surg. 1972 Jul;59(7):533–9.PubMedCrossRef
22.
Zurück zum Zitat Curran WJ, Jr, Kornstein MJ, Brooks JJ, Turrisi AT, 3rd. Invasive thymoma: the role of mediastinal irradiation following complete or incomplete surgical resection. J Clin Oncol. 1988 Nov;6(11):1722–7.PubMed Curran WJ, Jr, Kornstein MJ, Brooks JJ, Turrisi AT, 3rd. Invasive thymoma: the role of mediastinal irradiation following complete or incomplete surgical resection. J Clin Oncol. 1988 Nov;6(11):1722–7.PubMed
23.
Zurück zum Zitat Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. Ann Thorac Surg. 2003 Sep;76(3):878–84; discussion 884–5.PubMedCrossRef Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. Ann Thorac Surg. 2003 Sep;76(3):878–84; discussion 884–5.PubMedCrossRef
24.
Zurück zum Zitat Loehrer PJ S, Chen M, Kim K, Aisner SC, Einhorn LH, Livingston R, et al. Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial. J Clin Oncol. 1997 Sep;15(9):3093–9.PubMed Loehrer PJ S, Chen M, Kim K, Aisner SC, Einhorn LH, Livingston R, et al. Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial. J Clin Oncol. 1997 Sep;15(9):3093–9.PubMed
25.
Zurück zum Zitat Macchiarini P, Chella A, Ducci F, Rossi B, Testi C, Bevilacqua G, et al. Neoadjuvant chemotherapy, surgery, and postoperative radiation therapy for invasive thymoma. Cancer. 1991 Aug 15;68(4):706–13.PubMedCrossRef Macchiarini P, Chella A, Ducci F, Rossi B, Testi C, Bevilacqua G, et al. Neoadjuvant chemotherapy, surgery, and postoperative radiation therapy for invasive thymoma. Cancer. 1991 Aug 15;68(4):706–13.PubMedCrossRef
26.
Zurück zum Zitat Kim ES, Putnam JB, Komaki R, Walsh GL, Ro JY, Shin HJ, et al. Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer. 2004 Jun;44(3):369–79.PubMedCrossRef Kim ES, Putnam JB, Komaki R, Walsh GL, Ro JY, Shin HJ, et al. Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer. 2004 Jun;44(3):369–79.PubMedCrossRef
27.
Zurück zum Zitat Fornasiero A, Daniele O, Ghiotto C, Piazza M, Fiore-Donati L, Calabro F, et al. Chemotherapy for invasive thymoma. A 13-year experience. Cancer. 1991 Jul 1;68(1):30–3.PubMedCrossRef Fornasiero A, Daniele O, Ghiotto C, Piazza M, Fiore-Donati L, Calabro F, et al. Chemotherapy for invasive thymoma. A 13-year experience. Cancer. 1991 Jul 1;68(1):30–3.PubMedCrossRef
28.
Zurück zum Zitat Berruti A, Borasio P, Gerbino A, Gorzegno G, Moschini T, Tampellini M, et al. Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience. Br J Cancer. 1999 Nov;81(5):841–5.PubMedCrossRef Berruti A, Borasio P, Gerbino A, Gorzegno G, Moschini T, Tampellini M, et al. Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience. Br J Cancer. 1999 Nov;81(5):841–5.PubMedCrossRef
29.
Zurück zum Zitat Rea F, Sartori F, Loy M, Calabro F, Fornasiero A, Daniele O, et al. Chemotherapy and operation for invasive thymoma. J Thorac Cardiovasc Surg. 1993 Sep;106(3):543–9.PubMed Rea F, Sartori F, Loy M, Calabro F, Fornasiero A, Daniele O, et al. Chemotherapy and operation for invasive thymoma. J Thorac Cardiovasc Surg. 1993 Sep;106(3):543–9.PubMed
30.
Zurück zum Zitat Loehrer PJ S, Kim K, Aisner SC, Livingston R, Einhorn LH, Johnson D, et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol. 1994 Jun;12(6):1164–8.PubMed Loehrer PJ S, Kim K, Aisner SC, Livingston R, Einhorn LH, Johnson D, et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol. 1994 Jun;12(6):1164–8.PubMed
31.
Zurück zum Zitat Kim ES, Putnam JB, Komaki R, Walsh GL, Ro JY, Shin HJ, et al. Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer. 2004 Jun;44(3):369–79.PubMedCrossRef Kim ES, Putnam JB, Komaki R, Walsh GL, Ro JY, Shin HJ, et al. Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer. 2004 Jun;44(3):369–79.PubMedCrossRef
32.
Zurück zum Zitat Shin DM, Walsh GL, Komaki R, Putnam JB, Nesbitt J, Ro JY, et al. A multidisciplinary approach to therapy for unresectable malignant thymoma. Ann Intern Med. 1998 Jul 15;129(2):100–4.PubMed Shin DM, Walsh GL, Komaki R, Putnam JB, Nesbitt J, Ro JY, et al. A multidisciplinary approach to therapy for unresectable malignant thymoma. Ann Intern Med. 1998 Jul 15;129(2):100–4.PubMed
33.
Zurück zum Zitat Loehrer PJ S, Jiroutek M, Aisner S, Aisner J, Green M, Thomas CR, Jr, et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. Cancer. 2001 Jun 1;91(11):2010–5.PubMedCrossRef Loehrer PJ S, Jiroutek M, Aisner S, Aisner J, Green M, Thomas CR, Jr, et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. Cancer. 2001 Jun 1;91(11):2010–5.PubMedCrossRef
34.
Zurück zum Zitat Giaccone G, Ardizzoni A, Kirkpatrick A, Clerico M, Sahmoud T, van Zandwijk N. Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol. 1996 Mar;14(3):814–20.PubMed Giaccone G, Ardizzoni A, Kirkpatrick A, Clerico M, Sahmoud T, van Zandwijk N. Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol. 1996 Mar;14(3):814–20.PubMed
35.
Zurück zum Zitat Macchiarini P, Chella A, Ducci F, Rossi B, Testi C, Bevilacqua G, et al. Neoadjuvant chemotherapy, surgery, and postoperative radiation therapy for invasive thymoma. Cancer. 1991 Aug 15;68(4):706–13.PubMedCrossRef Macchiarini P, Chella A, Ducci F, Rossi B, Testi C, Bevilacqua G, et al. Neoadjuvant chemotherapy, surgery, and postoperative radiation therapy for invasive thymoma. Cancer. 1991 Aug 15;68(4):706–13.PubMedCrossRef
36.
Zurück zum Zitat Lemma GL, Lee JW, Aisner SC, Langer CJ, Tester WJ, Johnson DH, et al. Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol. 2011 May 20;29(15):2060–5.PubMedCrossRef Lemma GL, Lee JW, Aisner SC, Langer CJ, Tester WJ, Johnson DH, et al. Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol. 2011 May 20;29(15):2060–5.PubMedCrossRef
37.
Zurück zum Zitat Loehrer PJ, Yiannoutsos CT, Dropcho S, Burns M, Helft P, Chiorean EG, et al. A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma. J Clin Oncol. 2006;24:18s.CrossRef Loehrer PJ, Yiannoutsos CT, Dropcho S, Burns M, Helft P, Chiorean EG, et al. A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma. J Clin Oncol. 2006;24:18s.CrossRef
38.
Zurück zum Zitat Reubi JC, Waser B, Horisberger U, Krenning E, Lamberts SW, Gebbers JO, et al. In vitro autoradiographic and in vivo scintigraphic localization of somatostatin receptors in human lymphatic tissue. Blood. 1993 Oct 1;82(7):2143–51.PubMed Reubi JC, Waser B, Horisberger U, Krenning E, Lamberts SW, Gebbers JO, et al. In vitro autoradiographic and in vivo scintigraphic localization of somatostatin receptors in human lymphatic tissue. Blood. 1993 Oct 1;82(7):2143–51.PubMed
39.
Zurück zum Zitat Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993 Aug;20(8):716–31.PubMedCrossRef Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993 Aug;20(8):716–31.PubMedCrossRef
40.
Zurück zum Zitat Ferone D, van Hagen PM, van Koetsveld PM, Zuijderwijk J, Mooy DM, Lichtenauer-Kaligis EG, et al. In vitro characterization of somatostatin receptors in the human thymus and effects of somatostatin and octreotide on cultured thymic epithelial cells. Endocrinology. 1999 Jan;140(1):373–80.PubMedCrossRef Ferone D, van Hagen PM, van Koetsveld PM, Zuijderwijk J, Mooy DM, Lichtenauer-Kaligis EG, et al. In vitro characterization of somatostatin receptors in the human thymus and effects of somatostatin and octreotide on cultured thymic epithelial cells. Endocrinology. 1999 Jan;140(1):373–80.PubMedCrossRef
41.
Zurück zum Zitat Palmieri G, Montella L, Martignetti A, Muto P, Di Vizio D, De Chiara A, et al. Somatostatin analogs and prednisone in advanced refractory thymic tumors. Cancer. 2002 Mar 1;94(5):1414–20.PubMedCrossRef Palmieri G, Montella L, Martignetti A, Muto P, Di Vizio D, De Chiara A, et al. Somatostatin analogs and prednisone in advanced refractory thymic tumors. Cancer. 2002 Mar 1;94(5):1414–20.PubMedCrossRef
42.
Zurück zum Zitat Loehrer PJS, Wang W, Johnson DH, Aisner SC, Ettinger DS, Eastern Cooperative Oncology Group Phase II Trial. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial. J Clin Oncol. 2004 Jan 15;22(2):293–9. Loehrer PJS, Wang W, Johnson DH, Aisner SC, Ettinger DS, Eastern Cooperative Oncology Group Phase II Trial. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial. J Clin Oncol. 2004 Jan 15;22(2):293–9.
43.
Zurück zum Zitat Schalke B. Treatment of unresectable thymoma with neoadjuvant octreotide LAR. J Clin Oncol. 2010;28 (abstr.13540). Schalke B. Treatment of unresectable thymoma with neoadjuvant octreotide LAR. J Clin Oncol. 2010;28 (abstr.13540).
44.
Zurück zum Zitat Kurup A, Burns M, Dropcho S, Pao W, Loehrer PJ. Phase II study of gefitinib treatment in advanced thymic malignancies. J Clin Oncol. 2005;23:16s (abstr 7068). Kurup A, Burns M, Dropcho S, Pao W, Loehrer PJ. Phase II study of gefitinib treatment in advanced thymic malignancies. J Clin Oncol. 2005;23:16s (abstr 7068).
45.
Zurück zum Zitat Bedano PM, Perkins S, Burns M. A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma. J Clin Oncol. 2008;26:713s (abstr. 19087). Bedano PM, Perkins S, Burns M. A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma. J Clin Oncol. 2008;26:713s (abstr. 19087).
46.
Zurück zum Zitat Pan CC, Chen PC, Chiang H. KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. J Pathol. 2004 Mar;202(3):375–81.PubMedCrossRef Pan CC, Chen PC, Chiang H. KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. J Pathol. 2004 Mar;202(3):375–81.PubMedCrossRef
47.
Zurück zum Zitat Salter JT, Lewis D, Yiannoutsos PJ. Imatinib for the treatment of thmyic carcinoma. J Clin Oncol 2008;26:452s (abstr. 8116). Salter JT, Lewis D, Yiannoutsos PJ. Imatinib for the treatment of thmyic carcinoma. J Clin Oncol 2008;26:452s (abstr. 8116).
48.
Zurück zum Zitat Giaccone G, Rajan A, Ruijter R, Smit E, van Groeningen C, Hogendoorn PC. Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas. J Thorac Oncol. 2009 Oct;4(10):1270–3.PubMedCrossRef Giaccone G, Rajan A, Ruijter R, Smit E, van Groeningen C, Hogendoorn PC. Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas. J Thorac Oncol. 2009 Oct;4(10):1270–3.PubMedCrossRef
49.
Zurück zum Zitat Giaccone G, Rajan A, Berman A, Kelly RJ, Szabo E, Lopez-Chavez A, et al. Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. J Clin Oncol. 2011 May 20;29(15):2052–9.PubMedCrossRef Giaccone G, Rajan A, Berman A, Kelly RJ, Szabo E, Lopez-Chavez A, et al. Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. J Clin Oncol. 2011 May 20;29(15):2052–9.PubMedCrossRef
Metadaten
Titel
Thymic malignancies focusing on systemic treatment
verfasst von
Gudrun Absenger, MD
Ferdinand Ploner
Publikationsdatum
01.02.2013
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2013
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-013-0069-9

Weitere Artikel der Ausgabe 1/2013

memo - Magazine of European Medical Oncology 1/2013 Zur Ausgabe